Autonomix Medical (NASDAQ:AMIX – Get Free Report) and Pulse Biosciences (NASDAQ:PLSE – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.
Profitability
This table compares Autonomix Medical and Pulse Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autonomix Medical | N/A | -213.42% | -172.57% |
| Pulse Biosciences | N/A | -67.70% | -58.89% |
Insider and Institutional Ownership
10.8% of Autonomix Medical shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 6.2% of Autonomix Medical shares are held by insiders. Comparatively, 74.6% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autonomix Medical | N/A | N/A | -$11.41 million | ($4.65) | -0.09 |
| Pulse Biosciences | N/A | N/A | -$53.58 million | ($1.13) | -12.05 |
Pulse Biosciences is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Autonomix Medical and Pulse Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autonomix Medical | 1 | 1 | 1 | 0 | 2.00 |
| Pulse Biosciences | 1 | 0 | 1 | 0 | 2.00 |
Autonomix Medical currently has a consensus target price of $5.00, suggesting a potential upside of 1,150.00%. Pulse Biosciences has a consensus target price of $22.00, suggesting a potential upside of 61.53%. Given Autonomix Medical’s higher probable upside, analysts plainly believe Autonomix Medical is more favorable than Pulse Biosciences.
Volatility and Risk
Autonomix Medical has a beta of -2.59, indicating that its stock price is 359% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500.
Summary
Pulse Biosciences beats Autonomix Medical on 6 of the 9 factors compared between the two stocks.
About Autonomix Medical
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
